Zydus Wellness Q2 FY25 sales up 12% at Rs. 490.7 Cr
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
This product will be manufactured at Lupin’s Nagpur facility in India
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Subscribe To Our Newsletter & Stay Updated